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This research was carried out to develop a new carrier in dry powder aerosols. Two types of cyclodextrin were
chosen; g cyclodextrin (GCD) and dimethyl-b-cyclodextrin (DMCD) as carriers in dry powder formulations.
Salbutamol was used as a model drug and a control formulation containing lactose and the drug was included. A
twin-stage impinger (TSI) was used to evaluate in delivery eciency of those dry powder formulations. The toxicity
of cyclodextrin complexes was investigated in the rat by monitoring blood urea nitrogen (BUN) and urinary
creatinine, as well as determining haemolysis of human red blood cells. The release of salbutamol from dry powder
formulations was also studied over a period of time. From the results obtained, it was found that the formulation
containing GCD-enhanced drug delivery to the lower stage of the TSI (deposition=65%) much greater than that of
both formulations containing DMCD (50%) and the control formulation (40%) (P50?05). After injecting the
GCD complex BUN and creatinine levels in rats were similar to those obtained in the control while those receiving
DMCD complex had higher BUN and creatinine. The haemolysis of red blood cells incubated with the DMCD
complex was higher than that obtained in the GCD complex. The drug release in both formulations containing
GCD and DMCD was fast (over 70% was released in 5min) and nearly all the drug was released within 30min. It
can be concluded that GCD and DMCD are able to promote salbutamol delivery in dry powder inhaler compared
to a formulation containing lactose. In addition, GCD is relatively safe in the rat if the amount of GCD in the
formulation is similar to this experiment.
Key words: carrier; cyclodextrins; salbutamol; dry powder formulation.
RESPIR. MED. (2001) 95, 513–519 # 2001 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2001) 95, 513–519
doi:10.1053/rmed.2001.1079, available online at http://www.idealibrary.com onIntroduction
Inclusion complexes of various drugs with cyclodextrin
(CD) have been successfully applied in pharmaceutical
formulation to enhance solubility, chemical stability and
absorption (1–3). A relationship between partition co-
ecient of the drug and its tendency to form inclusion
complexes has been generally found, which indicates that
the hydrophobic cavity of CDs is more attractive to
lipophilic guest molecules (1). There are considerable
pharmaceutical benefits to be gained from a drug molecule
forming an inclusion complex with natural and modified
CDs such as dimethyl-b-cyclodextrin (DMCD) and hydro-
xypropyl-b-cyclodextrin (HPCD) (4,5). There have been a
few applications of using CD as a drug carrier in aerosolsReceived 30 November 2000 and accepted in revised form 12
March 2001.
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0954-6111/01/060513+07 $35?00/0(6). If there is proof that a cyclodextrin–drug complex
results in enhanced drug delivery, this field would be of
interest, as this gives rise to the possibility of the eventual
reduction of the dose of a given drug when used with
cyclodextrins. However, the cyclodextrin toxicity should
also be of concern. In this study, salbutamol was chosen as
a model drug as it is a very common drug used in dry
powder inhalers. There is evidence that the target site of this
drug was mostly in the lower airways (7), but to date, the
delivery eciency of targeted drug to the lower airways is
only 10% of the nominal dose (8,9).
Intra-nasal administration of DMCD and b-oestradiol or
progesterone was studied by Schipper et al. (10). It was
found that the formation of steroid inclusion complexes
was an important factor in enhancing its absorption. The
nasal dosage form of insulin complexed with DMCD
greatly increased serum insulin in the rat compared to the
dosage form without CD (11). The enhanced rates of
dissolution lead to improved biological activities of the
complexed drugs.
In this study, two types of CDs; g cyclodextrin (GCD)
and DMCD were chosen as a carrier. The reason for this is# 2001 HARCOURT PUBLISHERS LTD
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solubilizer and has been used in an opthalmic preparation
(13); therefore it is a good candidate for low irritation
material.
The aims of this study was to evaluate the amount of
drug and carrier entering the lower stage of the twin-stage
impinger (TSI). The TSI is an ocial in-vitro model for the
evaluation of inhalers in British Pharmacopoeia (1998). As
the delivery of the inhaler was divided into two fractions,
namely, upper and lower stage deposition which were once
used to represent upper and lower airway deposition,
respectively. The interaction between salbutamol and
cyclodextrin would be identified. The salbutamol–CD
complex was administered to animal to test toxicity. The
final aim was to investigate the dissolution rate of
salbutamol in dry powder dosage form.
Materials and methods
Racemic+salbutamol was obtained from Allchem Inter-
national Ltd (Berkshire, U.K.). GCD and DMCD were
obtained from Wacker Chemie Ltd (Burghausen, Ger-
many). Heptanesulfonic acid and urea kits were purchased
from Sigma Chemicals (St. Louis, MO, U.S.A.). Urea was
obtained from Unilab (NSW, Australia). All HPLC grade
solvents were purchased from J.T. Baker (Philadelphia, PA,
U.S.A.). The other reagents were of analytical grade and
used without further purification.
PREFORMED CYCLODEXTRIN–
SALBUTAMOL COMPLEXES
An amount of salbutamol base (30mg) was weighed into
2?5ml Chromacol1 vials (Sci-VI system, U.S.A.). To each
vial, 1 ml of different concentrations of either GCD or
DMCD (2, 4, 6, 8 and 10mg%) in water was added. The
suspensions in the vials were capped and shaken in a water
bath shaker at 378C for 48 h. After equilibration was
attained (2 days), the solution was centrifuged at 800 g for
5min and an aliquot of clear solution was sampled and
analysed for salbutamol content by using an ultraviolet
spectrophotometer (Spectronic Genesis, New York,
U.S.A.).
A 100ml of each sample was appropriately diluted with
water and its absorbance was determined at 225 nm.
Stability constant of 1 : 1 complexes was detected from the
slope and intercept of straight line of the phase solubility




The freeze-dried complexes were obtained by adding
equimolar concentrations of the cyclodextrins solution to
racemic salbutamol. The clear solution of a mixture was
then freeze-dried for 48 h until yielding a solid cake. The
solid cake was micronized with air jet micronizer (FrymaJet, Rheinfelden, Switzerland) before use as an ingredient
in dry powder formulation (2?90mm). The product was
kept in a well-closed container and stored in environ-
mental chamber at 258C and 45% relative humidity. The
prepared complexes of salbutamol with cyclodextrin
were characterized by infrared spectroscopy with a Perkin
Elmer FT-IR Model 1600 spectrophotometer (Norwalk,
CT, U.S.A), Perkin Elmer differential scanning calorimetry
(DSC, CT, U.S.A.) and Philips X-ray diffractometry
(XRD, PW 3710, The Netherlands).
DRY POWDER FORMULATION AND
DEPOSITION STUDIES
Five formulations made in-house were used; these con-
tained micronized lactose (70% of population510m)
mixed with micronized salbutamol (2?77+0?11mm) in a
ratio of 60 : 1 or cyclodextrin–salbutamol complexes
(2?90+0?15 mm) in a ratio of 30 : 1 and 60 : 1, respectively.
The formulation was prepared by mixing drug or drug
complexes with lactose in a V-shaped mixer (Mitsubishi,
Tokyo, Japan) for 1 h. The powder mix was filled into eight
blister disks of Diskhaler1 with a drug content of 400 mg
per disk. Subsequently, a disk loaded into Diskhaler1
device (Glaxo-Wellcome, Ware, U.K.) was aerosolized by
drawing air through the TSI (15) at flow rate of 60 lmin71
for 10 sec. Drug and cyclodextrin deposition on each stage
of the TSI were collected by washing with mobile phase and
their content was then determined by HPLC.
Salbutamol was analysed by a validated HPLC (Waters,
Milford, U.S.A.) using an ultraviolet detector set at a
wavelength of 225 nm. The assay conditions were: sta-
tionary phase, Zorbax ODS (15 cm64?6mm i.d.); mobile
phase, 0?06% heptanesulfonic acid adjusted with glacial
acetic acid to pH 4?5 methanol (60 : 40); flow rate
1mlmin71; injection volume 100ml; limit of detection
0?1 mgml71.
Cyclodextrin was analysed by HPLC (Waters) using a
refractive index detector. The conditions were: stationary
phase, Adsorbil NH2 (15 cm64?6mm i.d.); mobile phase,
80% acetonitrile in water; flow rate 1mlmin71; injection
volume 100 ml; limit of detection 1 mgml71.
The amounts of drug and cyclodextrin depositing in the
upper and lower stage of the TSI were expressed as a
percentage of the nominal dose. Each formulation was
tested six times.
TOXICITY STUDIES OF CYCLODEXTRIN–
SALBUTAMOL COMPLEX
Male Wistar rats (weight 190–210 g) were obtained from the
animal house, Faculty of Science, Prince of Songkhla
University, Hat-Yai, Thailand and housed for at least
1 week in the laboratory animal room prior to use. Then,
they received either salbutamol (200 mgml71), GCD com-
plex (1mgml71, 1ml), DMCD complex (1mgml71, 1ml)
or buffered normal saline solution pH 7?4 (1ml) by intra-
peritoneal injection. The rats were fasted overnight with
water ad libitum before collection of blood and urine. At 0 h
FIG. 1. Solubility curves of salbutamol in the presence of
cyclodextrin solutions [g cyclodextrin (GCD; ) and
dimethyl-b-cyclodextrin (DMCD; )] (mean+SD, n=4).
CYCLODEXTRIN AS A DRUG CARRIER IN SALBUTAMOL AEROSOLS(before drug administration), 24 h, 7 days and 1 month
after drug administration, the rats were anesthetized with
ether and blood was collected from the retro-orbital plexus
by capillary action for determination of blood chemistry.
Plasma was isolated by centrifugation of the whole blood
and collected with a micro-syringe. The plasma urea level
was determined for each experimental group of six rats. The




BUN concentration was measured by coupled enzyme
reactions involving urease and glutamate dehydrogenase
(BUN reagent) (16). A total 10 ml of plasma was added into
a sample cuvette containing 1ml of BUN reagent then the
cuvette was covered and gently mixed inversely for 30 sec.
The spectrophotometer was set at a wavelength of 340 nm
to read absorbance at exact time points of 30 and 90 sec,
respectively. The water was used as a blank. The difference
of absorbance values obtained at 90 and 30 sec, correlating
with BUN concentration linearly, were used to calculate
BUN levels compared to known concentrations.
URINARY CREATININE DETERMINATION
The detection method for urinary creatinine was adapted
from the Sigma catalogue (17). Urinary creatinine (100 ml)
reacted with picric acid (10 ml) under alkaline conditions
(adding 1ml of 0?1M NaOH) to form a yellow–orange
complex. Principally, the colour is derived from creatinine
as well as non-specific substances likely to be present in the
sample. On addition of acid (1ml of 0?1M HCl), the colour
contributed by creatinine is destroyed while the product of
non-specific substance remains. Thus, the difference in
colour intensity, measured at 500 nm before and after an
acidification, is proportional to creatinine concentration. In
this experiment, the standard creatinine in a range of 1–
50mg% was used to prepare a calibration curve.
RED BLOOD CELL HAEMOLYSIS STUDIES
Red blood cells were isolated from whole human blood by
centrifugation at 1000 g for 10min. The plasma was
removed and the red blood cells were resuspended in
buffered normal saline. Then, the cells were washed and
diluted to 2% with buffered normal saline pH 7?4.
Solutions of 0?1, 0?2, 0?4, 0?6, 0?8 and 1mg% of either
DMCD complex or GCD complex, buffered saline solution
and 200 mgml71 salbutamol were prepared by dissolving
an accurately weighed amount of the respective compound
in buffered normal saline and diluting to volume. Triton
X-100 (1% v/v) was used to provide 100% red blood cell
lysis (18). All solutions were stored at 378C before
being used to dilute red blood cells, followed by gentle
inversion. The samples were then incubated for 60min at
378C, after which time the red blood cells were viewedunder a haemocytometer microscopically (Olympus,
Tokyo, Japan). After incubation, the sample tubes were
centrifuged at 1500 g for 10min at room temperature and
the supernatant was decanted into the cuvette to read the
absorbance at 550 nm using an ultraviolet spectrophot-
ometer. The degree of haemolysis was reported as the
percentage haemoglobin released relative to the total
release caused by Triton X-100.
PREFORMED CYCLODEXTRIN–
SALBUTAMOL RELEASE STUDIES
A dissolution study was conducted using a condition
described by the British Pharmacopoeia for testing salbu-
tamol tablet formulations with the paddle method. The
dissolution medium was 200ml of water set at 378C. The
paddle rotated at 50 rpm. In this study, a semi-permeable
membrane (3 cm in diameter) obtained from Spectrum
(Texas, U.S.A.) with a molecular weight cut-off from 1000
was used. The membrane was prepared by cutting
approximately 6 cm lengths of membrane which was soaked
in water for 1 h prior to use. The freeze-dried complex
(200mg) was weighed into this membrane sac. The sac was
then clipped at both sides to avoid leakage and placed into
dissolution chamber. Samples were taken for each of the
two formulations every 5min up to 30min. Each experi-
ment was performed at least six times and the mean was
calculated in each case. The samples were analysed for the
quantity of salbutamol by HPLC (see analysis method).
Statistical analysis of data was performed by one-way
ANOVA. Differences were considered to be statistically
significant at P50?05.
Results and discussion
The solubility of salbutamol increased in the presence of
different types of cyclodextrins (DMCD, GCD) as com-
pared to that in water (Fig. 1). The profile of salbutamol
FIG. 2. Salbutamol delivered from different dry powder
formulations containing (1) GCD complex mixed with
lactose (1 : 30); (2) GCD complex mixed with lactose
(1 : 60); (3) DMCD complex mixed with lactose (1 : 30); (4)
DMCD complex mixed with lactose (1 : 60); (5)
salbutamol mixed with lactose (1 : 60) aerosolized at
60 lmin71 into a twin stage impinger (TSI) (mean+SD,
n=6). Upper stage ( ), lower stage ( ), % total ( ).
516 T. SRICHANA ET AL.solubility (y) in mM was plotted as a function of
cyclodextrin concentration (X) in mM. The slope from the







where m=molar ratio of drug to CD; k=stability constant
(complexation constant); S0=solubility of drug in the
absence of CD.
Stability constant of salbutamol and DMCD was
58?55M71 calculated from the above equation while this
value of drug with GCD was 12?7M71. This means that the
complex formation of DMCD with salbutamol is greater
than that of GCD. Molar ratio of drug to CD (m) was
found to be one that fitted the best in the Higuchi equation.
The freeze-dried complex powder was micronized under air
jet micronizer before use as an ingredient in the dry powder
formulation. Therefore, the size range of freeze-dried
complex was suitable for delivering the drug to the lower
stage of the TSI. It is common practice to confirm the
complex formation by IR, DSC and XRD. The IR spectra,
DSC curves and XRD patterns of freeze-dried products
(GCD and DMCD with salbutamol) support the evidence
of inclusion complexes (data not shown).
DEPOSITION STUDIES
After a blister disk containing eight doses was loaded into
the Diskhaler1 device (Glaxo-Wellcome), the air was
drawn through the device to deliver the DPI into the TSI
at a flow rate of 60 lmin71 for 10 sec. Drug and CD
deposition on each stage of the impinger was determined by
HPLC. Total emission of the drug from all five formula-
tions was higher than 85%. Drug penetration to the lower
stage of formulations 1 and 2 was around 65%, which was
significantly higher than that of the control formulation
(40%) (P50?01), as shown in Fig. 2. These results illustrate
that GCD is able to increase the penetration of salbutamol
into the lower stage of the impinger better than that of the
lactose carrier. The size of those complexes or of the pure
drug may not be involved in enhancing drug delivery
because they are relatively close to each other (2?7 and
2?9mm, respectively). Meanwhile, there was slightly less
drug being delivered to the lower stage (50% of the nominal
dose) in both formulations containing DMCD (formula-
tions 3 and 4), compared to those containing GCD.
However, all formulations containing CDs in this study
were superior in delivery of salbutamol compared with
lactose (40%). In addition, all upper stage drug deposition
of formulations containing CD was less than that of its
lower stage. This result was opposite to the formulation
containing lactose.
In cases of formulations containing more lactose
(formulations 2 and 4), drug delivery to lower stage was
slightly greater than those containing less lactose (formula-
tions 1 and 3). Again, it needs to be proved that the better
drug delivery is caused by the lower interaction between
drug–CD complex and lactose as in case of the GCD
formulation as compared to pure drug with lactose. It ispossible that pure drug allowed more interaction with
lactose than that with the complex. This should be
investigated further. For this, atomic force microscopy
may be an advantageous tool. Also, the in-vitro deposition
in all cases of CD complexes mixed with lactose was much
higher than lower stage deposition reported in the
literatures (8,9). Therefore, it is possible to use CD to
enhance delivery of salbutamol.
The freeze-dried complex promoted slightly higher drug
delivery to lower stages when a higher amount of lactose
carrier was present in the formulations. The GCD complex
was the better component in delivery of drug to lower
stages than that of the DMCD complex.
The deposition of CD was detected in both the upper and
lower stages of the impinger. The large amount of CD was
deposited in the lower stage of the impinger as shown in
Fig. 3 in all formulations. This also corresponded to a
larger amount of drug found in the lower stage compared to
the upper stage. The amount of CD in the lower stage was
about 1mg in all four formulations (Fig. 3), therefore this
amount was used to investigate further the possible toxicity
of CD in vivo.
The amount of GCD and DMCD deposited in the
lower stage of the impinger was higher in those containing
GCD. There was no statistical difference between those
formulations containing different amounts of lactose
which used the same CD. It is possible that CD will
interact with the drug as per cent ratios of CD to
salbutamol in both upper and lower stages are close to
unity in all formulations. This means that the deposition
pattern of the drug is similar to that of CD. This may be
because the complex modifies interactions between lactose
and salbutamol, subsequently changing deposition in the
lower stage.
FIG. 3. Cyclodextrin deposition on each stage of TSI
aerosolized from formulations containing (1) GCD
complex mixed with lactose (1 : 30); (2) GCD complex
mixed with lactose (1 : 60); (3) DMCD complex mixed
with lactose (1 : 30); (4) DMCD complex mixed with
lactose (1 : 60) (mean+SD, n=6). Upper stage ( ), lower
stage ( ).
FIG. 4. Blood urea nitrogen in the rat after intra-peritoneal
injection of salbutamol 200mgm71 (*), g-cyclodextrins
complex (GCD complex) ( ) and dimethyl-b-cyclodextrin
complex (DMCD complex) 1mgml71 ( ) compared with
control (*) at day 1, 7 and 30 (mean+SD, n=5).
FIG. 5. Urinary creatinine in rat after intraperitoneal
injection of salbutamol 200mgml71 (*), g-cycoldextrin
complex (GCD complex) ( ) and dimethyl-b-cycoldextrin
complex (DMCD complex) 1mgml71 ( ) compared with
control (*) at day 0, 1, 7 and 30 (mean+SD, n=5).
CYCLODEXTRIN AS A DRUG CARRIER IN SALBUTAMOL AEROSOLSTOXICITY STUDIES OF CD
Both types of CD complexes were given to the rats by intra-
peritoneal injection, as this provides contact of these agents
with cellular membranes and membrane components. The
plasma urea nitrogen and urinary creatinine were mon-
itored. As shown in Fig. 4, the urea nitrogen level in the
control group which received normal saline solution was 2–
4mg% over a period of 1 month. When salbutamol was
given, BUN was about 3–4mg% and the urea increased
after injection on day 1 to 5% and decreased to normal
levels at day 7.
While the rat was administered with the GCD complex,
the BUN slightly increased from day 0 to day 7 (2–3mg%)
and further increased (5mg%) after day 7 to day 30 (Fig.
4). However, the BUN value in this case was around 5mg%
over 1 month. The BUN increased to 10mg% at day 1 after
the DMCD complex injection, which was different from the
results obtained by injecting either normal saline solution,
salbutamol or GCD complex. BUN then decreased to 7?5%
and 6?5% at day 7 and day 30, respectively. As these results
were compared to three other cases, it can be concluded
that the possibility of toxicity to the kidney was highest
when using the DMCD complex. In the case of the GCD
complex, toxicity was not significantly higher when
compared to that of salbutamol or the control. Therefore,
the GCD complex was considered to be safe in this case as
compared to the DMCD complex. However, over the
concentrations used for all formulations in this study, BUN
was still less than 15mg% (this value was considered to be
normal). Plasma urea nitrogen was determined for the
DMCD complex, which was significantly higher than the
control group. These results may indicate that kidney
damage was due to the high concentration of urea detected
in the systemic circulation.As can be seen in Fig. 5, in the animal which received the
GCD complex, creatinine level increased from 7 to
8?15mg%, which was not significantly different from the
control (pooled data). These values, however, were much
higher for the DMCD complex. They increased to a level of
30mg% after 24 h and declined to 24mg% after 1 week.
Levels had returned to normal at 30 days. These results
indicate that the use of a GCD complex was safer than the
use of the DMCD complex, as the creatinine level was
considered to be normal.
In vitro haemolysis studies are not true predictors for in
vivo membrane interactions due to the dynamic association
behaviours of parenterally administered cyclodextrin with
FIG. 6. Haemolysis of human red blood cells incubated in
cyclodextrin complex solution and [GCD ( ) and DMCD
complex ( )] for 15min at various concentrations
(mean+SD, n=4).
FIG. 7. The release of salbutamol from salbutamol-
cyclodextrin complexes [GCD ( ) and DMCD complexes
( )] (mean+SD, n=6).
518 T. SRICHANA ET AL.endogenous compounds (19). However, haemolysis studies
do provide a rapid means for determining relative-
membrane comprising ability. The number of red blood
cells (rbc) in buffered isotonic solution was found to be 4?5
million cellsml71. When rbcs were mixed with cyclodex-
trins complex at various concentrations in buffered isotonic
solutions, it was found that slight haemolysis occurred as
the concentration of cyclodextrin complex increased from
0?1 to 1?0mgml71 with the degree of haemolysis about
1?3% (Fig. 6). The haemolysis of rbcs in the case of the
DMCD complex was slighly higher than that of using
overall concentrations of the GCD complex. It was
observed that at high concentration (1mg%), the haemo-
lytic rate of both the GCD and DMCD complex was not
significantly different; DMCD was still higher than that of
GCD. As the haemolysis of GCD and DMCD complexes
was not different from that of the isotonic buffer (around
1%), it is reasonable to be used over the concentration
range studied. It is apparent that the haemolytic activity of
GCD complex was slightly less than that of the DMCD
complex. For example, haemolysis at 1mg% of DMCD
and GCD caused haemolysis of about 1?4 and 1?3%,
respectively. These results suggest that the cyclodextrins
used are unlikely to cause red blood cell damage under the
conditions studied. In the case of salbutamol, haemolysis
was not different from that of normal saline solution. Also,
light microscope indicated no changes in the shape of
erythrocytes similar to that in the control even at a
concentration of 200 mgml71.
PREFORMED CYCLODEXTRIN–
SALBUTAMOL DISSOLUTION STUDIES
The release of salbutamol through a semi-permeable
membrane into the dissolution medium was tested in order
to allow only the drug molecule to permeate, while keepingcyclodextrin molecules within the semi-permeable
membrane sac. In Fig. 7, it can be seen that the total
release of salbutamol over 80% was achieved in both
types of salbutamol–CD complexes (30min). There was
relatively fast release in vitro. The GCD complex released
salbutamol slower than that of the DMCD complex. These
differences were significant at a level of 0?05. This
corresponded to its solubility curve i.e. salbutamol
dissolved with a higher amount in DMCD solution
compared to that in the GCD solution (Fig. 1). From the
stability constant, it may be expected that the release of
GCD complex would be faster than that of the DMCD
complex. However, this result was not the case, which
was in agreement with other experiments; the higher
stability constant gave better release from the com-
plexes (20,21).
Conclusions
It was demonstrated that the solubility and dissolution rate
of salbutamol were improved by forming the inclusion
complex with CD. DMCD gave higher solubility and
dissolution rates than those of GCD. The present work
also showed the potential of using GCD and DMCD as a
good carrier in dry powder inhaler. Both CDs are able
to form complex with salbutamol while giving a larger
drug delivery to the lower stage. Moreover, the GCD
and DMCD complex are unlikely to cause nephrotoxicity
or cell damages as indicated by blood urea nitrogen
and creatinine level. Salbutamol release occurred over a
short period of time, serving the purpose of a rapid onset
drug. Therefore, it is reasonable to consider GCD and
DMCD as an alternative carrier. The GCD has greater
potential to be used to enhance salbutamol to the lower
stage of the TSI as improved drug delivery was achieved.
Pharmacokinetics and toxicity in man should also be
studied further.
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